Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two antidepressant drugs, dosulepin (also known as dothiepin) and sertraline. Dosulepin is a tricyclic antidepressant (TCA) that acts primarily as a serotonin–norepinephrine reuptake inhibitor, with additional antihistamine, anticholinergic, antiadrenergic, antiserotonergic, and sodium channel-blocking effects[2][5]. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic activity in the central nervous system by inhibiting the presynaptic reuptake of serotonin[3]. Both are used for the treatment of depression; sertraline is also indicated for obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. The combination does not have an established unique indication or brand formulation; co-administration may be considered in rare clinical scenarios but carries significant risk due to pharmacokinetic interactions—SSRIs like sertraline can increase plasma levels of TCAs like dosulepin—and increased risk of side effects including serotonin syndrome[4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dosulepin + sertraline.